Aerodynamic deposition of combination dry powder inhaler formulations in vitro: A comparison of three impactors

International Journal of Pharmaceutics

Volumn 388, Issue 1-2, 2010, Pages 40-51

  Taki, Mohammed ^a   Marriott, Christopher ^a   Zeng, Xian Ming ^b   Martin, Gary P ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b TEVA Pharmaceuticals   (United States)

Author keywords

Aerodynamic deposition; Andersen cascade impactor; Combination; Dry powder inhaler; Multi stage liquid impinger; Next generation impactor

Indexed keywords

FLUTICASONE PROPIONATE PLUS SALMETEROL;

AEROSOL; AIRFLOW; ARTICLE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRY POWDER; FLOW RATE; IN VITRO STUDY; PARTICLE SIZE; POWDER INHALER; PRESSURE; PRIORITY JOURNAL;

ADMINISTRATION, INHALATION; AEROSOLS; ALBUTEROL; ANDROSTADIENES; BRONCHODILATOR AGENTS; DRUG COMBINATIONS; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; POWDERS; TECHNOLOGY, PHARMACEUTICAL;

EID: 76549128675     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2009.12.031     Document Type: Article

References (59)

1. Asking L., and Olsson B. Calibration at different flow rates of a multistage liquid impinger. Aerosol Sci. Technol. 27 (1997) 39-49
2. Auty R.M., Brown K., Neale M.G., and Snashall P.D. Respiratory tract deposition of sodium cromoglycate is highly dependent upon technique of inhalation using the spinhaler. Br. J. Dis. Chest 81 (1987) 371-380
3. Bates D.V., Fish B.R., Hatch T.F., Mercer T.T., and Morrow P.E. Deposition and retention models for internal dosimetry of the human respiratory tract. Task group on lung dynamics. Health Phys. 12 (1966) 173-207
4. Berg E., Svensson J.O., and Asking L. MMAD based on dose to impactor rather than on delivered dose. In: Dalby R.N., Byron P.R., and Peart J. (Eds). Respiratory Drug Delivery VIII (2002), Davis Harwood International, Raleigh 339-342
5. British Pharmacopoeia (BP). Aerodynamic Assessment of Fine Particles-Fine Particle Dose and Particle Size Distribution, Appendix XII C (2008), The Stationery Office, London, UK
6. Broeders M.E.A.C., Molema J., Vermue N.A., and Folgering H.T.M. Peak inspiratory flow rate and slope of the inhalation profiles in dry powder inhalers. Eur. Respir. J. 18 (2001) 780-783
7. Chan H.K., Clark A., Gonda I., Mumenthaler M., and Hsu C. Spray dried powders and powder blends of recombinant human deoxyribonuclease (rhDNase) for aerosol delivery. Pharm. Res. 14 (1997) 431-437
8. Chavan V., and Dalby R. Novel system to investigate the effects of inhaled volume and rates of rise in simulated inspiratory air flow on fine particle output from a dry powder inhaler. AAPS PharmSci (2002) 4
9. Chew N.Y.K., and Chan H.K. In vitro aerosol performance and dose uniformity between the Foradile Aerolizer and the Oxis Turbuhaler. J. Aerosol Med.: Deposit. Clear. Eff. Lung 14 (2001) 495-501
10. Coates M.S., Chan H.K., Fletcher D.F., and Raper J.A. Influence of air flow on the performance of a dry powder inhaler using computational and experimental analyses. Pharm. Res. 22 (2005) 1445-1453
11. De Boer A.H., Gjaltema D., and Hagedoorn P. Inhalation characteristics and their effects on in vitro drug delivery front dry powder inhalers. Part 2. Effect of peak flow rate (PIFR) and inspiration time on the in vitro drug release from three different types of commercial dry powder inhalers. Int. J. Pharm. 138 (1996) 45-56
12. Dolovich M. Measurement of particle size characteristics of metered dose inhaler (MDI) aerosols. J. Aerosol Med. 4 (1991) 251-263
13. Dunbar C., Kataya A., and Tiangbe T. Reducing bounce effects in the Andersen cascade impactor. Int. J. Pharm. 301 (2005) 25-32
14. Dunbar C., and Mitchell J. Analysis of cascade impactor mass distributions. J. Aerosol Med.: Deposit. Clear. Eff. Lung 18 (2005) 439-451
15. El-Araud K.A., Clark B.J., Kaahwa C., Anum P., and Chrystyn H. The effect of dose on the characterization of aerodynamic particle-size distributions of beclomethasone dipropionate metered-dose inhalers. J. Pharm. Pharmacol. 50 (1998) 1081-1085
16. Ganderton D. General factors influencing drug delivery to the lung. Respir. Med. 91 (1997) 13-16
17. Gonda I. Targeting by deposition. In: Hickey A.J. (Ed). Pharmaceutical Inhalation Aerosol Technology (1992), Marcel Dekker Inc., New York 61-82
18. GSK. Prescribing Information (Advair Diskus 100/50, 250/50, 500/50) (2007)
19. Heyder J., Gebhart J., Rudolf G., Schiller C.F., and Stahlhofen W. Deposition of particles in the human respiratory tract in the size range 0.005-15 [mu]m. J. Aerosol Sci. 17 (1986) 811-825
20. Kamiya A., Sakagami M., Hindle M., and Byron P.R. Aerodynamic sizing of metered dose inhalers: an evaluation of the Andersen and next generation pharmaceutical impactors and their USP methods. J. Pharm. Sci. 93 (2004) 1828-1837
21. Lim J.G.P., Shah B., Rohatagi S., and Bell A. Development of a dry powder inhaler, the Ultrahaler, containing triamcinolone acetonide using in vitro-in vivo relationships. Am. J. Ther. 13 (2006) 32-42
22. Malton C.A., Hallworth G.W., and Padfield J.M. The association and particle size distribution of drug and surfactant discharged from a metered-dose inhalation aerosol. J. Pharm. Pharmacol. 34 (1982) 65P
23. Marple V.A., Olson B.A., and Miller N.C. The role of inertial particle collectors in evaluating pharmaceutical aerosol delivery systems. J. Aerosol Med.: Deposit. Clear. Eff. Lung 11 (1998) S139-S153
24. Marple V.A., Olson B.A., Santhanakrishnan K., Mitchell J.P., Murray S.C., and Hudson-Curtis B.L. Next generation pharmaceutical impactor (a new impactor for pharmaceutical inhaler testing). Part II. Archival calibration. J. Aerosol Med.: Deposit. Clear. Eff. Lung 16 (2003) 301-324
25. Marple V.A., Roberts D.L., Romay F.J., Miller N.C., Truman K.G., Van Oort M., Olsson B., Holroyd M.J., Mitchell J.P., and Hochrainer D. Next generation pharmaceutical impactor (a new impactor for pharmaceutical inhaler testing). Part I. Design. J. Aerosol Med.: Deposit. Clear. Eff. Lung 16 (2003) 283-299
26. Masoud O. The In Vitro Assessment of Aerosolised Drug Deposition Using Novel Oropharyngeal Models (2004), Department of Pharmacy, King's College London, University of London, London
27. Meakin B.J., Cainey J.M., and Woodcock P.M. Simulated 'in-use' and 'mis-use' aspects of the delivery of terbutaline sulphate from Bricanyl Turbohaler(TM) dry powder inhalers. Int. J. Pharm. 119 (1995) 103-108
28. Miller N.C., Ross D.L., and Nas M.M. Effect of formulation factors on the observed bounce in cascade impactors used to measure the spray particle size of metered dose inhalers. Int. J. Pharm. 173 (1998) 93-102
29. Mitchell J.P., Costa P.A., and Waters S. An assessment of an Andersen mark-II cascade impactor. J. Aerosol Sci. 19 (1988) 213-221
30. Mitchell J.P., and Nagel M.W. Cascade impactors for the size characterization of aerosols from medical inhalers: their uses and limitations. J. Aerosol Med.: Deposit. Clear. Eff. Lung 16 (2003) 341-377
31. Mitchell J.P., and Nagel M.W. Particle size analysis of aerosols from medicinal inhalers. KONA 22 (2004) 32-65
32. Mitchell J.P., Nagel M.W., Wiersema K.J., and Doyle C.C. Aerodynamic particle size analysis of aerosols from pressurized metered-dose inhalers: comparison of Andersen 8-stage cascade impactor, next generation pharmaceutical impactor, and model 3321 aerodynamic particle sizer aerosol spectrometer. AAPS PharmSciTech 4 (2003) Article 54
33. Nasr M.M., Ross D.L., and Miller N.C. Effect of drug load and plate coating on the particle size distribution of a commercial albuterol metered dose inhaler (MDI) determined using the Andersen and Marple-Miller cascade impactors. Pharm. Res. 14 (1997) 1437-1443
34. Newman S.P., and Clarke S.W. Therapeutic aerosols 1-physical and practical considerations. Thorax 38 (1983) 881-886
35. Nichols S.C. Andersen cascade impactor: calibration and mensuration issues for the standard and modified impactor. Pharmeuropa 12 (2000) 584-588
36. Nichols S.C., Brown D.R., and Smurthwaite M. New concept for the variable flow rate Andersen cascade impactor and calibration data. J. Aerosol Med.: Deposit. Clear. Eff. Lung 11 (1998) S133-S138
37. Olsson B., Asking L., and Johansson M. Choosing a cascade impactor. In: Dalby R.N., Byron P.R., and Farr S.J. (Eds). Respiratory Drug Delivery VI (1998), Interpharm Press, Buffalo Grove, IL 133-138
38. Pauwels R., Newman S., and Borgstrom L. Airway deposition and airway effects of antiasthma drugs delivered from metered-dose inhalers. Eur. Respir. J. 10 (1997) 2127-2138
39. Pedersen S., Hansen O.R., and Fuglsang G. Influence of inspiratory flow rate upon the effect of a Turbuhaler. Arch. Dis. Child. 65 (1990) 308-310
40. Ph. Eur. Consistency of Formulated Preparations: Fine Particle Dose and Particle Size Distribution (2004), European Pharmacopoeia, European Directorate for the Quality of Medicines and Healthcare
41. Prime D., Grant A.C., Slater A.L., and Woodhouse R.N. A critical comparison of the dose delivery characteristics of four alternative inhalation devices delivering salbutamol: pressurized metered dose inhaler, Diskus inhaler, Diskhaler inhaler, and Turbuhaler inhaler. J. Aerosol Med.: Deposit. Clear. Eff. Lung 12 (1999) 75-84
42. Roberts D.L., and Chiruta M. Transient impactor behavior during the testing of dry-powder inhalers via compendial methods. Drug Delivery to the Lungs 18 (2007), The Aerosol Society, Edinburgh pp. 202-205
43. Roberts D.L., and Romay F.J. Relationship of stage mensuration data to the performance of new and used cascade impactors. J. Aerosol Med.: Deposit. Clear. Eff. Lung 18 (2005) 396-413
44. Rudolf G., Kobrich R., and Stahlhofen W. Modelling and algebraic formulation of regional aerosol deposition in man. J. Aerosol Sci. 21 (1990) S403-S406
45. Sethuraman V.V., and Hickey A.J. Evaluation preseparator performance for the 8-stage nonviable Andersen impactor. AAPS PharmSciTech 2 (2001) Article 4
46. Shelton C., Woodrow B., and Holberg W. Performance comparison of Copley and Andersen 8-stage cascade impactors. Drug Delivery to the Lungs 13 (2002), The Aerosol Society, London pp. 176-179
47. Srichana T. A Study of Some Factors Affecting the Deposition of Drug and Excipients Following Aerosolisation of Dry Powders (1998), Department of Pharmacy, King's College London, University of London, London
48. Stein S.W. Size distribution measurements of metered dose inhalers using Andersen Mark II cascade impactors. Int. J. Pharm. 186 (1999) 43-52
49. Stein S.W., and Olson B.A. Variability in size distribution measurements obtained using multiple Andersen Mark II cascade impactors. Pharm. Res. 14 (1997) 1718-1725
50. Subba Rao G.N., Banick D.W., and Pacenti D.M. Particle size distribution of a suspension aerosol using Andersen and Marple-Miller cascade impactors. Pharm. Res. 14 (1997) 1272-1274
51. Tarsin W., Assi K.H., and Chrystyn H. In-vitro intra- and inter-inhaler flow rate-dependent dosage emission from a combination of budesonide and eformoterol in a dry powder inhaler. J. Aerosol Med.: Deposit. Clear. Eff. Lung 17 (2004) 25-32
52. Tarsin W., Pearson S.B., Assi K.H., and Chrystyn H. Emitted dose estimates from Seretide Diskus and Symbicort Turbuhaler following inhalation by severe asthmatics. Int. J. Pharm. 316 (2006) 131-137
53. Thermo Electron Corporation. Instruction Manual for the Series 20-800: Eight Stage Non-viable Impactor (2003), Thermo Electron Corporation, Franklin, MA
54. Thiel C.G. Can in vitro particle size measurements be used to predict pulmonary deposition of aerosol from inhalers?. J. Aerosol Med.: Deposit. Clear. Eff. Lung 11 (1998) S43-S52
55. USP. Physical Tests-Aerosols (2006), United States Pharmacopeia 29, pp. 2620-2621
56. Vaughan N.P. The Andersen impactor: calibration, wall losses and numerical simulation. J. Aerosol Sci. 20 (1989) 67-90
57. Weda M., Zanen P., Boer A.H.D., Barends D.M., and Frijlink H.W. An investigation into the predictive value of cascade impactor results for side effects of inhaled salbutamol. Int. J. Pharm. 287 (2004) 79-87
58. Weda M., Zanen P., De Boer A.H., Gjaltema D., Ajaoud A., Barends D.M., and Frijlink H.W. Equivalence testing of salbutamol dry powder inhalers: in vitro impaction results versus in vivo efficacy. Int. J. Pharm. 249 (2002) 247-255
59. Yang T.T., Li S., Wyka B., and Kenyom D. Drug delivery performance of the mometasone furoate dry powder inhaler. J. Aerosol Med.: Deposit. Clear. Eff. Lung 14 (2001) 487-494